Company Overview and News

2
The 'outliers': 23 top companies lack women in top leadership

2018-09-03 theage.com.au
There are just 14 female chief executives running the top 200 listed companies and only 24 female chief financial officers, a new snapshot of corporate Australia's shows, amid calls for the quick promotion of women in business line roles.
PILBF JBHHY JHIUF LYSCF EVN SNDFY MALRY SCPAF SOUTF SRXTY MIN CCLAY CCL GWAXY INCZY SFR CAHPF WNARF WSA PLS SRX SXMDF GMA BWP JHX JHX CCLAF JBH WHC SXL TNE SFRRF LYSDY MALRF SCP EHE ICPVF IPL

2
The 'outliers': 23 top companies lack women in top leadership

2018-09-03 smh.com.au
There are just 14 female chief executives running the top 200 listed companies and only 24 female chief financial officers, a new snapshot of corporate Australia's shows, amid calls for the quick promotion of women in business line roles.
PILBF JBHHY JHIUF LYSCF EVN SNDFY MALRY SCPAF SOUTF SRXTY MIN CCLAY CCL GWAXY INCZY SFR CAHPF WNARF WSA PLS SRX SXMDF GMA BWP JHX JHX CCLAF JBH WHC SXL TNE SFRRF LYSDY MALRF SCP EHE ICPVF IPL

2
ASX lifts modestly on materials as supermarkets fall

2018-08-20 theage.com.au
The sharemarket ended a volatile day of trading modestly higher, as gains in the materials sector outweighed losses in banks and supermarkets.
SRX RTPPF RIO SXMDF RIO RIO RTNTF SRXTY OGFGF SGF OGFGY ORG

2
ASX lifts modestly on materials as supermarkets fall

2018-08-20 smh.com.au
The sharemarket ended a volatile day of trading modestly higher, as gains in the materials sector outweighed losses in banks and supermarkets.
SRX RTPPF RIO SXMDF RIO RIO RTNTF SRXTY OGFGF SGF OGFGY ORG

2
Delcath: A Potential 2,900% Share Count Increase Could Make The Stock Price Decline

2018-08-07 seekingalpha - 1
Delcath is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
ANGO SRX SXMDF DCTH SRXTY DCTHD

 
Australia's Sirtex clears U.S. regulatory hurdle for Chinese buyout

2018-07-16 reuters
(Reuters) - Liver cancer treatment maker Sirtex Medical (SRX.AX) said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through.
SRX SXMDF VAR SRXTY

 
Deals of the day-Mergers and acquisitions

2018-07-03 reuters
July 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:
SRX SXMDF SCGLF JNP CTLT SCGLY SRXTY GLE

 
UPDATE 1-Australia's Sirtex gets FIRB nod for Chinese buyout

2018-07-03 reuters
(Reuters) - Liver cancer treatment maker Sirtex Medical (SRX.AX) said on Tuesday Australia’s Foreign Investment Review Board (FIRB) had approved its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through.
SRX SXMDF VAR SRXTY

48
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

2018-06-18 zacks
Chicago, IL – June 18, 2018 – Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific (BSX - Free Report) , Stryker Corporation (SYK - Free Report) , Medtronic (MDT - Free Report) , Abbott (ABT - Free Report) and Varian Medical (VAR - Free Report) .
SRX ELY SXMDF SAPGF ENSG SRXTY GIII MDT SAP BSX IFNNY SYK KMG IFNNF DLA

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks - 1
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

162
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 malaymail
SYDNEY, June 15 — Didi Chuxing Technology Co Ltd, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies Inc, will begin offering its service this month in Australia, its first foray in a Western-style country.
SRX SXMDF VAR AAPL SRXTY 9984 SFTBF SFTBY

6
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 theage.com.au
Didi Chuxing Technology Co, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies, says it will begin offering its service this month in Australia, its first foray in a Western country.
SRX SXMDF VAR SRXTY 9984 SFTBF SFTBY

 
Donald Trump unlikely to turn away $1.9b Chinese bid, says Sirtex boss

2018-06-15 theage.com.au
Donald Trump’s diplomatic tensions with China are unlikely to stop regulatory approval of the $1.9 billion takeover deal headed by China's CDH Investments of Sirtex Medical, says chief executive Andrew McLean.
SRX SXMDF SRXTY

4
Sirtex agrees to takeover by China's CDH

2018-06-15 perthnow.com.au
Liver cancer treatment developer Sirtex Medical has accepted a $1.87 billion takeover bid from China's CDH Genetech after another suitor, Varian Medical Systems of the US, declined to match or beat CDH's offer.
SRX SXMDF VAR SRXTY

6
Chinese ride-sharing giant Didi picks Australia for first Western foray

2018-06-15 smh.com.au
Didi Chuxing Technology Co, the Chinese ride-sharing company that bought the mainland operations of Uber Technologies, says it will begin offering its service this month in Australia, its first foray in a Western country.
SRX SXMDF VAR SRXTY 9984 SFTBF SFTBY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...